Objective: Androgen receptor (AR) plays an important role in male breast cancer (MBC). Additionally, endocrine therapy is the most important treatment in oestrogen receptor (ER)-positive advanced breast cancer. This study was aimed to investigate the role of AR in MBC treatment and prognosis and to analyse the relationship between AR and the effect of tamoxifen treatment in MBC patients. Methods: AR protein levels and other tumour characteristics (e.g. expression of ER (ESR1), PR (PGR), AR, HER2 (ERBB2) and Ki-67 (MKI67)) in breast cancer tissue from 102 MBC patients were determined using immunohistochemical analysis. Additionally, the relationship between AR status and clinicopathological features was analysed using the c 2 -test. Association with survival was initially analysed using the Kaplan-Meier method and the log-rank test, and Cox regression analysis was used to adjust for other prognostic indicators.
Introduction
Male breast cancer (MBC) is an uncommon disease, accounting for w1% of all breast cancer cases and less than 1% of all malignancies in men (1, 2) . Several factors have been reported to influence the risk of breast carcinoma in men. These include clinical conditions causing hypoandrogenism (e.g. Klinefelter's syndrome, testicular trauma and infertility), liver cirrhosis causing hyperoestrogenism, the use of exogenous oestrogens, obesity or gynaecomastia (1, 3, 4, 5, 6) . All of these studies have suggested that MBC is an endocrine-related malignancy.
Owing to the rarity of MBC, large prospective randomised trials have become difficult to perform. Therefore, clinical decision-making in MBC patients has historically been made based on extrapolation from female breast cancer (FBC) studies. Oestrogen receptor (ER) is the most important target of endocrinotherapy in breast cancer patients. Tamoxifen, which blocks the action of oestrogen in breast tissue by binding to ER, is also considered the golden standard in endocrinotherapy for MBC patients. Previous studies have shown that breast cancer is more often ER-and progesterone receptor (PR)-positive in male patients than in female patients, suggesting that most patients with MBC will be sensitive to anti-hormonal therapies such as tamoxifen (7) . However, Wang-Rodriguez and colleagues found better survival in ER-positive patients but did not find a benefit from treatment with tamoxifen (8) (http://www.pubmed central.nih.gov/articlerender.fcgi?artidZ314449&toolZ pmcentrez -B8). Recently, a Sweden study has found that patients undergoing adjuvant endocrine treatment had a poorer breast cancer survival compared with those cases without such treatment (9) . The distinct hormone signal in both genders may be the cause of their different responses to anti-hormonal therapy. The type of MBC patients who can benefit from endocrine therapy should be investigated.
Oestrogen has been shown to play a critical role in the development and progression of breast cancer in women. Recently, the male sex hormone androgen has been shown to cause regression of breast cancers in rats (10) and to suppress the growth of breast cancer cell lines via androgen receptor (AR) (11) . Additionally, an epidemiological survey showed that an increased risk of MBC is observed in patients with hypoandrogenism and gynaecomastia. Androgen is the dominant sex hormone in males, thus AR can play an important role in the development and progression of MBC. However, the role of AR in MBC treatment and prognosis is poorly understood. Pich et al. (12) showed a lack of association between AR and survival in MBC, whereas Munoz de Toro et al. (13) suggested that decreased androgen action (AR-negative) within the breast might contribute to an earlier development of MBC. By contrast, Eliza et al. (14) found a strong correlation between AR expression and decreased 5-year overall survival (OS) and disease-free survival (DFS). The different results may be because of different sensitivities to endocrine therapy. Thus far, and to the best of our knowledge, no study has investigated the relationship between AR and benefit from tamoxifen treatment therapy in MBC patients.
In this study, we investigated sex hormone receptor expression in a large population of MBC patients and found decreased survival rates in patients with AR expression and/or lymph node metastases. Further analyses showed that this decreased survival rate in AR-positive patients can be the consequence of their poor response to tamoxifen therapy. 
Materials and methods

Specimens
Immunohistochemistry
A monoclonal mouse antihuman AR antibody (Dako, Glostrup, Denmark) was used to evaluate AR expression, and the monoclonal rabbit antihuman ER, PR, HER-2 and Ki67 antibodies (Zhongshan Bio. Beijing, China) were used to evaluate the expressions of ER (ESR1), PR (PGR), HER2 (ERBB2) and Ki-67 (MKI67). The labelled streptavidin-biotin kit used was obtained from Zhongshan Bio. Company. The morphology was evaluated using a BX51 microscope (Olympus). Tissue samples were formalin fixed and embedded in paraffin. Tissue sections of 4-mm thickness were cut from the tissue blocks, and immunohistochemical staining for ER, PR, AR, HER2 and Ki-67 was carried out according to the manufacturer's instructions. Briefly, sections were transferred onto adhesive slides and were dried at 60 8C for 30 min. After incubation with the primary antibodies, immunodetection was performed using biotinylated antimouse immunoglobulin, followed by peroxidase-labelled streptavidin. The labelled streptavidin-biotin kit was used, and 3,3 0 -diaminobenzidine chromogen was used as a substrate. The sections were observed under a light microscope (!400). Phosphatebuffered saline was used to replace the primary antibody and served as the negative control. Additionally, appropriate control tissues were used as positive controls. Sections were considered AR positive when O10% of tumour cell nuclei stained positive. For ER and PR, nuclear staining in more than 1% of tumour cells was classified as positive staining (16) . A positive HER2 stain (17) was determined by greater than 2C membranous staining of tumour cells based on the conventional three-tier grading criteria. The Ki-67 values were expressed as the percentage of positive cells in each case. All of the stained sections were evaluated independently by two pathologists. In rare cases, if the pathologists disagreed with the findings, the slides were re-evaluated using a multiheaded microscope. Final agreement was achieved in all of the cases.
Statistical methods
The relationship between AR status and clinicopathological features was analysed using the c 2 -test. Association with survival was initially analysed using the KaplanMeier method and the log-rank test, and Cox regression analysis was used to adjust for other prognostic indicators. P!0.05 was considered to be statistically significant. OS was calculated from the date of surgery until death or the date patients were last known to be alive. DFS was calculated from the date of surgery until relapse or the date patients were last known to be alive.
Results
Clinicopathological features of the 102 MBC patients
The median age at diagnosis was 61 years (range: 29-88 years). The cases were diagnosed as follows: 95 invasive ductal carcinomas; six invasive lobular carcinomas and one ductal carcinoma in situ. Tumour grades were scored and distributed as follows: grade IZ12 (11.8%) cases; grade IIZ76 (74.5%) cases and grade IIIZ14 (13.7%) cases. Lymph 
Expression of AR and other sex hormone receptors in MBC patients
In MBC patients, the AR protein was primarily expressed in cell nuclei at a moderate intensity (Fig. 1 ) and was observed in 41 (40.2%) cases. ER was expressed in 87 of the 102 cases (85.3%), whereas PR expression was observed in 72 cases (70.6%).
The correlation between the expression of AR and other parameters is shown in Table 1 . AR expression was not correlated with T-stage, histological grade, HER2 status and the status of other sex hormone receptors. However, the rate of AR expression was found to be significantly higher in cases with lymph node metastases (PZ0.032).
AR expression predicts a short DFS and OS
The 5-year OS and DFS rates were 65 and 52%, respectively, for the entire group. Compared with AR-negative patients, AR-positive patients showed significantly shorter 5-year OS rates (54 vs 72% respectively; PZ0.045) and 5-year DFS rates (39 VS 61% respectively; PZ0.026; Fig. 2A and B) . The 5-year OS and DSF rates were also decreased in the patients with lymph node metastases (PZ0.031 for OS; PZ0.036 for DFS). There was no significant difference in either OS or DFS rates with respect to ER, PR and HER2 status. The results are given in Table 2 . Multivariate survival analysis was performed by testing the adverse factors identified in univariate analysis in the Cox model. Only AR status (for DFS: PZ0.042, hazard ratioZ 1.857, 95% CIZ1.097-2.432; for OS: PZ0.027, hazard ratioZ2.720, 95% CIZ1.066-8.776) retained independent prognostic significance for both DFS and OS.
AR-positive patients show a poor response to tamoxifen therapy
Twenty-nine patients received tamoxifen treatment after relapse. The clinical benefit rate (CR CPR CSD) for tamoxifen treatment was 51.7% as summarised in Table 3 . Compared with AR-positive patients, AR-negative patients showed a higher clinical benefit rate (71 vs 25% respectively; PZ0.025). The median TTP and OS were also significantly different in AR-positive patients compared with AR-negative patients (PZ0.02 for TTP, PZ0.029 for OS). One patient (ERC, PRC and ARK) with lung and bone metastases achieved a complete response 
Discussion
Owing to its rarity, specific treatment guidelines for MBC are lacking. Thus, male patients are treated according to the guidelines for FBC. Recent studies have indicated that males have a poorer survival than females, despite having received adjuvant treatment to the same extent (18, 19) . Although breast carcinoma in both genders shares certain characteristics, there are notable differences in incidence, age distribution, sex hormone receptor expression, prognosis and survival. A present study showed the high median age of the onset of MBC (61 years), about ten years older than that in FBC in China (20) . It is well known that sex hormone imbalance plays an important role in breast cancer development. Previous studies have shown that breast cancer is more often hormone receptor (ER and PR) positive in MBC patients than in FBC patients (21) .
In line with these data, we found higher ER and PR expression rates in the 102 MBC patients -85.3 and 70.6% respectively -values that are higher than those reported in the literature (21) . The AR expression rate was 40.2% in this study, a value that was similar to that reported by other investigators (12, 14) , but much lower than that reported in FBC patients (22) . Compared with women, men usually have lower oestrogen and higher androgen levels. The difference in sex hormone receptor status between MBC and FBC may originate from the negative feedback regulation of their corresponding hormone levels. Unlike other studies on FBC or MBC, we found no correlation between AR and ER/PR status (14, 23) . There was no association between AR and age, tumour size, histological grade and HER2 status, and these results are in accordance with those in reports on FBC and MBC as well (12, 14, 23) . However, the AR expression rate was found to be significantly higher in cases with lymph node metastases, suggesting that AR-positive MBC tends to be more aggressive than AR-negative MBC. AR appears to be closely associated with the aggressiveness of MBC. A previous report has demonstrated that PR was associated with MBC aggressiveness (24); however, there is no association between PR and the aggressiveness of MBC in our study. Now, the role of PR in MBC is still uncertain. The discrepancies may be attributed to the small number of patients, differences in methodology, patient selection bias or other factors not yet realised. MBC is usually more advanced at diagnosis than FBC. The OS for MBC patients has ranged between 49 and 87% at 5 years (14, 25) . A more advanced stage and a higher incidence of lymph node metastases have been linked to a poorer prognosis (26) . The role of AR as a prognostic factor is controversial. In MBC, Pich et al. (12) showed the lack of association between AR and survival, whereas Munoz de Toro et al. (13) suggested that decreased androgen action within the breast might contribute to earlier development of MBC. However, similar to the results obtained by Eliza Kwiatkowska et al. (14) , we found a strong correlation between AR expression and the OS and DFS of MBC patients. AR-positive expression was associated with adverse prognosis and AR status had prognostic significance in both univariate and multivariate analyses. In addition, for the first time, we studied the relationship between AR status and tamoxifen response in metastatic MBC patients and found that AR-positive patients have a poor clinical benefit rate than AR-negative patients. Certain reports have shown that AR over-expression induces tamoxifen resistance in human breast cancer, and they speculate that AR and ERa could collaborate to regulate cyclin D1 gene expression and promote cell cycle progression in tamoxifen-resistant cells (27) . It has been demonstrated that the AR amino-terminal domain and ERa ligand-binding domain can interfere with each other via oestrogen (28) . It was reported that ERa and AR complexes can regulate EGFR phosphorylation (c-ErbB2) through c-Src signalling (29) . Similar to the crosstalk of ERa, AR-mediated resistance may be influenced by the crosstalk between AR and other signalling pathways. Thus, the cause of the resistance to tamoxifen therapy in AR-positive MBC patients remains to be elucidated.
In this study, the case number was limited, and definitive conclusions could be drawn. However, our results provided a hint regarding the relationship between AR expression and clinical therapy in MBC. As androgen is the dominant sex hormone in males, targeting the AR pathway might just be a potential therapeutic tool in MBC.
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